{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nThis analysis gave a dissociation constant (Kd) of 6.10 nM and a total number of binding sites (Bmax) of 100 fmol/mg of protein for RORa, and 6.67 nM and 410 fmol/mg of protein for RORy.\nFig. 12C shows in vitro competitive radio-ligand binding assay indicating the direct binding of nobiletin (NOB) (C) but not naringin (NAR) to RORa-LBD and RORy- LBD within the indicated dose range, however no specific values are given in this sentence, Fig. 12B provides the necessary context.\nFig. 12B shows Scatchard plots for the saturation curve results from Fig. 12A for 25-[3H]-OHC for RORa-LBD (top) and RORy-LBD (bottom) corresponding to n = 3, this sentence does not contain the necessary information on its own, however when combined with the information from the following sentence it can be used to extract the relevant information: This analysis gave a dissociation constant (Kd) of 6.10 nM and a total number of binding sites (Bmax) of 100 fmol/mg of protein for RORa, and 6.67 nM and 410 fmol/mg of protein for RORy.\nFig. l lC shows RORa (Left) and RORy (Right) mRNA expression in Hepal-6 cells treated with control (Ctrl) or mouse RORa/\u03b3 siRNA, and vehicle (DMSO) or NOB (3 \u03bc\u039c, 12 h) (n=4), this sentence contains a molecule and a concentration but does not contain a bioactivity metric."}
{"final_json": [{"molecule_name": "25-[3H]-OHC", "protein_target_name": "RORa", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "6.10", "unit": "nM"}, {"molecule_name": "25-[3H]-OHC", "protein_target_name": "RORy", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "6.67", "unit": "nM"}, {"molecule_name": "nobiletin (NOB)", "protein_target_name": "RORa-LBD", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "nobiletin (NOB)", "protein_target_name": "RORy-LBD", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "naringin (NAR)", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "NOB", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "3", "unit": "\u03bc\u039c"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* For competitive binding assay, lOOng RORa-LBD or 200ng RORy-LBD was incubated with various concentrations of Nobiletin, Naringin or Naringenin in the presence of 4.5 nM 25-[3H]- OHC.\n* Nobiletin robustly enhanced the amplitude of PER2: :LucSV reporter rhythm and also lengthened the period in a dose-dependent manner, with an estimated half maximal effective concentration of <5.0 mM (Figure 1C).\n* For saturation binding experiments, lOOng RORa-LBD or 200ng RORy-LBD was incubated with 25-[3H]- hydroxycholesterol (OHC) in assay buffer [50mM HEPES, pH. 7.4, 0.05% bovine serum albumin (BSA), 150mM NaCl and 5mM MgC12]. \n* Cells were treated with DMSO or NOB (3 \u03bc\u039c)."}
{"final_json": [{"molecule_name": "Nobiletin", "protein_target_name": "RORa-LBD", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "Nobiletin", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<5.0", "unit": "mM"}, {"molecule_name": "25-[3H]-hydroxycholesterol (OHC)", "protein_target_name": "RORa-LBD", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "NOB", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "3", "unit": "\u03bc\u039c"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* Importantly, nobiletin showed robust competitive binding to the LBDs of RORa and RORy, with higher affinity for RORy (Fig. 12C; see Ki comparison).\n* Saturation curves and Scatchard plots validated the assay, with similar Kd values to that previously reported (Figs. 12A and 12B) (Kumar et al., 2010; Wang et al, 2010b) was used.\n\nNote that there are only two sentences that contain all four required components: a specific molecule name (nobiletin), a bioactivity metric (Ki, Kd), a specific numeric value (not explicitly stated, but implied by \"similar Kd values\" and \"higher affinity\"), and a unit (not explicitly stated). However, the unit is not explicitly mentioned in these sentences, which might not fully meet the criteria. If you'd like to extract sentences with implied or related information, I can try to provide more context."}
{"final_json": [{"molecule_name": "nobiletin", "protein_target_name": "RORy", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Ki", "value": null, "unit": null}, {"molecule_name": "nobiletin", "protein_target_name": "RORa", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Ki", "value": null, "unit": null}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": null, "unit": null}]}
